Intervention Review

Rivastigmine for Alzheimer's disease

  1. Jacqueline Birks1,*,
  2. John Grimley Evans2,
  3. Vasso Iakovidou3,
  4. Magda Tsolaki4

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 8 JUL 2009

Assessed as up-to-date: 8 SEP 2008

DOI: 10.1002/14651858.CD001191.pub2

Database Title

Additional Information

How to Cite

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD001191. DOI: 10.1002/14651858.CD001191.pub2.

Author Information

  1. 1

    University of Oxford, Centre for Statistics in Medicine, Oxford, UK

  2. 2

    University of Oxford, Division of Clinical Geratology, Nuffield Department of Clinical Medicine, Oxford, UK

  3. 3

    Thessaloniki, Makedonia, Greece

  4. 4

    Aristotle University of Thessaloniki, 3rd Neurology Department, Thessaloniki, Macedonia, Greece

*Jacqueline Birks, Centre for Statistics in Medicine, University of Oxford, Wolfson College, Linton Road, Oxford, OX2 6UD, UK. jacqueline.birks@csm.ox.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 8 JUL 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (61K)Standard (547K)Full (1599K)

  1. Current Version

    Rivastigmine for Alzheimer's disease

    Jacqueline Birks, John Grimley Evans, Vasso Iakovidou and Magda Tsolaki

    Article first published online: 8 JUL 2009 | DOI: 10.1002/14651858.CD001191.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Rivastigmine for Alzheimer's disease

    Jacqueline Birks, John Grimley Evans, Vasso Iakovidou and Magda Tsolaki

    Article first published online: 21 JAN 2009 | DOI: 10.1002/14651858.CD001191

View Full Article (HTML) Summary (61K)Standard (547K)Full (1599K)